RxDoctor Payments Data

William Philippi, MD

Neurology · Augusta, GANPI 1881692010

Payments from drug & device makers

$13,423in general payments, 2019–2025

Across 600 payments — averaging $22.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Novartis$854
  • Amgen$831
  • MDD US Operations, LLC$605
  • UCB, Inc.$577
  • EMD Serono, Inc.$465
  • plus $6K from 52 others

What the payments were for

  • Speaking & faculty fees$2,25017%
  • Food & beverage$11,08383%
  • Education$901%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)157$4,020
Novartis43$854
Amgen40$831
MDD US Operations, LLC19$605
UCB, Inc.26$577
EMD Serono, Inc.17$465
Biogen22$438
SK Life Science, Inc.15$432
Eisai Inc.15$410
Lundbeck LLC16$380
Lilly USA, LLC20$315
Johnson & Johnson10$297
AstraZeneca(2 entities)13$282
Pfizer16$269
Neurocrine Biosciences, Inc.10$244
Argenx US, Inc.7$242
Otsuka America Pharmaceutical, Inc.8$238
Sunovion Pharmaceuticals Inc.22$218
TG Therapeutics, Inc.6$194
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC7$136
Supernus Pharmaceuticals, Inc.9$135
Biohaven Pharmaceutical Holding Company Ltd.9$133
GE HealthCare7$120
Genentech USA, Inc.5$98
Mallinckrodt Enterprises LLC5$96
Grifols USA, LLC5$94
ANI Pharmaceuticals, Inc.3$90
Amneal Pharmaceuticals LLC6$90
Biohaven Pharmaceuticals, Inc.5$90
Acadia Pharmaceuticals Inc4$81
Acorda Therapeutics, Inc4$74
Mallinckrodt Hospital Products Inc.3$70
Sanofi2$67
Corcept Therapeutics4$65
Novo Nordisk4$60
Teva Pharmaceuticals USA, Inc.3$52
Radius Health, Inc.3$46
Kedrion Biopharma, Inc.2$43
Insulet Corporation3$41
Vanda Pharmaceuticals Inc.2$41
Boston Scientific2$31
Portola Pharmaceuticals, LLC2$30
Bristol Myers Squibb2$29
Shire North American Group Inc2$29
Neurelis, Inc.1$25
Cycle Pharmaceuticals Inc1$25
Banner Life Sciences, LLC1$25
Kyowa Kirin, Inc.2$24
Viatris Specialty LLC1$24
Catalyst Pharmaceuticals, Inc.1$23
Livanova USA, Inc.1$21
Braintree Laboratories, Inc.1$19
Impel Pharmaceuticals Inc.1$18
Takeda Pharmaceuticals U.S.A., Inc.1$15
Assertio Therapeutics, Inc.1$15
Upsher-smith Laboratories LLC1$14
Xeris Pharmaceuticals, Inc.1$13
SPR Therapeutics, Inc1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,423 in reported general payments places this provider in the 75th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$113,929
Medicare patients
571
Services billed
974

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole12$18,846
RytaryCarbidopa/Levodopa13$15,721
Lacosamide27$9,783
DilantinPhenytoin Sodium Extended22$6,411
Levetiracetam169$4,268
Dimethyl Fumarate21$3,890
Gabapentin147$3,661
Pregabalin113$2,220
Donepezil Hcl281$2,186
Memantine Hcl83$1,904
Memantine Hcl ErMemantine Hcl20$1,841
Carbidopa-LevodopaCarbidopa/Levodopa94$1,697
Pyridostigmine Bromide14$1,395
Phenytoin Sodium Extended44$1,284
Carbidopa-Levodopa ErCarbidopa/Levodopa33$1,280

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$238$18,84612 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$90$17,11727 claims
PfizerDilantin$269$6,41122 claims
Upsher-smith Laboratories LLCTopiramate$14$44543 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 506 neurology providers in Georgia.

Other neurology in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →